Atossa Therapeutics

Historical price data

Atossa Therapeutics is a focused, clinical-stage biopharmaceutical company with a singular mission to transform breast cancer care through its proprietary compound, (Z)-endoxifen. Its strategy centers on developing this highly potent SERM across multiple high-need breast cancer indications, including metastatic disease, representing a high-conviction, platform-like approach with a single multi-indication asset. The company operates as a lean, development-focused entity, channeling resources into clinical trials designed to demonstrate the efficacy and safety of its novel candidate.

Proprietary development and oral formulation of (Z)-endoxifen, a highly potent selective estrogen receptor modulator (SERM) designed to be nearly 100 times more potent than other SERMs like tamoxifen with a goal of improved tolerability.

Competes in the crowded breast cancer space against generic tamoxifen, aromatase inhibitors, injectable and oral SERDs (e.g., fulvestrant, elacestrant), and combination regimens with CDK4/6 inhibitors. Aims to differentiate on the basis of superior potency and an improved tolerability profile for its oral (Z)-endoxifen formulation.